eliprodil

Eliprodil is a small molecule, investigational drug that acts as a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, with selectivity for the NR2B (GluN2B) subunit at submicromolar concentrations[3][5][6]. It also exhibits activity as a calcium channel blocker and has been described as neuroprotective[1][5]. Eliprodil was developed primarily for neurological indications such as acute ischemic stroke, traumatic brain injury, Parkinson's disease, and other movement disorders[1][2][3]. The drug failed to demonstrate efficacy in Phase III clinical trials for acute ischemic stroke and head injuries and its development was discontinued for these indications by Synthélabo Recherche (now part of Sanofi)[3][7].

Other names

(4-chlorophenyl)-4-((4-fluorophenyl)methyl)-1-piperidineethanol